Literature DB >> 23426704

Highly-sensitive C-reactive protein, a biomarker of cardiovascular disease risk, in radically-treated differentiated thyroid carcinoma patients after repeated thyroid hormone withholding.

A Piciu1, D Piciu, R J Marlowe, A Irimie.   

Abstract

AIMS: In patients radically treated for differentiated thyroid carcinoma, we assessed the response of highly-sensitive C-reactive protein, an inflammatory biomarker for cardiovascular risk, after thyroid hormone withholding ("deprivation"), as well as factors potentially influencing this response.
MATERIAL AND METHODS: We included 52 adults (mean age 45.6±14.0 years, 35 females) who were disease-free after total thyroidectomy, radioiodine ablation and chronic thyroid hormone therapy. They were lifelong non-smokers without apparent inflammatory comorbidity, cardiovascular history beyond pharmacotherapy-controlled hypertension, anti-dyslipidemic medication, or C-reactive protein >10 mg/L in any study measurement. The index deprivation lasted ≥2 weeks, elevating serum thyrotropin >40 mIU/L or ≥100 × the individual's suppressed level. We examined the relationship of age, number of prior deprivations, and gender with the magnitude of post-deprivation C-reactive protein concentration through multivariable statistical analyses using the F test on linear regression models.
RESULTS: Post-deprivation, C-reactive protein reached intermediate cardiovascular risk levels (based on general population studies involving chronic elevation), 1-3 mg/L, in 44.2% of patients and high-risk levels, >3 mg/L, in another 17.3%. Mean C-reactive protein was 1.77±1.50 mg/L, differing significantly in females (2.12±1.66 mg/L) vs. males (1.05±0.69 mg/L, P <0.001). In multivariable analysis, patients ≤45 years old (odds ratio, 95% confidence interval 0.164 [0.049-0.548]) were less likely, and females, more likely (3.571 [1.062-12.009]) to have post-deprivation C-reactive protein ≥1 mg/L.
CONCLUSIONS: Thyroid hormone withdrawal frequently elevated C-reactive protein to levels that when present chronically, were associated with increased cardiovascular risk in general population studies. © J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23426704     DOI: 10.1055/s-0032-1333230

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  2 in total

1.  EVALUATION OF CARDIOVASCULAR RISK AND MYOCARDIAL PERFUSION IN PATIENTS WITH RADICALLY TREATED DIFFERENTIATED THYROID CARCINOMA AND REPEATED EPISODES OF IATROGENIC HYPOTHYROIDISM.

Authors:  M Saftencu; E Barbus; C Pestean; A Piciu; D Piciu
Journal:  Acta Endocrinol (Buchar)       Date:  2016 Jan-Mar       Impact factor: 0.877

2.  Psychological impact of 131I radioprotection measures on thyroid cancer patients.

Authors:  Elena Barbus; Claudiu Pestean; Maria Iulia Larg; Katalin Gabora; Eduard-Alexandru Bonci; Claudiu Badulescu; Andra Piciu
Journal:  Clujul Med       Date:  2018-10-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.